BETAPREDICT - MS patients treated with BETAferon®: PREDICTors of treatment adherence

Study identification

• PURI:
  https://redirect.ema.europa.eu/resource/39640
• EU PAS number:
  EUPAS10249
• Study ID:
  39640
• Official title and acronym:
  BETAPREDICT - MS patients treated with BETAferon®: PREDICTors of treatment adherence
• DARWIN EU® study:
  No
• Study countries:
  Germany
• Study description:
  This study aims to evaluate potential predictors of adherence by investigating a representative cohort of MS patients in Germany treated with Betaferon
• Study status:
  Finalised

Research institutions and networks

Institutions

Multiple centres: 35 centres are involved in the study

Study timelines

Date when funding contract was signed

Planned: 15/07/2015

Actual: 15/07/2015

Study start date

Planned: 15/08/2015

Actual: 08/09/2015

Date of final study report

Planned: 01/11/2020

Actual: 09/12/2020

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Bayer

Study protocol

Initial protocol

18016_Protocol

Updated protocol

18016_Study Protocol_Redacted_V1.0_2015-02-12

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable